Transitional Cell Carcinoma of the Bladder Clinical Trial
Official title:
Phase II Single Arm, Open Label, Single Institution Study of Continuous Sunitinib (Sutent) in Patients With High-Risk (BCG-Refractory) Superficial Transitional Cell Carcinoma (TCC) of the Bladder
RATIONALE: Sunitinib malate may stop the growth of tumor cells by blocking some of the
enzymes needed for cell growth or by blocking blood flow to the tumor.
PURPOSE: This phase II trial is studying how well sunitinib malate works in treating patients
with recurrent transitional cell bladder cancer.
PRIMARY OBJECTIVES:
I. To determine the clinical efficacy of oral sunitinib (Sutent) given continuously for a
maximum of 12 weeks, with respect to complete response rates at 12 months after completion of
treatment in patients with high-risk superficial bladder cancer who have failed previous
intravesical BCG.
SECONDARY OBJECTIVES:
I. To assess the impact of sunitinib treatment in recurrence-free survival, progression-free
survival, and overall survival in patients with high-risk superficial TCC of the bladder who
have failed previous intravesical BCG.
II. To evaluate the safety and tolerability of sunitinib (Sutent) administered in patients
with high-risk superficial TCC of the bladder who have failed previous intravesical BCG.
TERTIARY OBJECTIVES:
I. To assess pre-treatment tissue baseline angiogenic markers and to evaluate the magnitude
of the difference among these variables with post-treatment tumor tissue after treatment with
sunitinib (Sutent).
II. To evaluate the effects of Sunitinib (Sutent) on immunosuppressive regulatory T cells
(Tregs).
III. To determine the presence of circulating tumor cells in superficial BCG-refractory TCC
patients.
OUTLINE:
Patients receive oral sunitinib malate once daily on days 1-28. Treatment repeats every 28
days for 3 courses in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up periodically.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02897765 -
A Personal Cancer Vaccine (NEO-PV-01) w/ Nivolumab for Patients With Melanoma, Lung Cancer or Bladder Cancer
|
Phase 1 | |
Terminated |
NCT00112905 -
Sorafenib in Treating Patients With Regional or Metastatic Cancer of the Urothelium
|
Phase 2 | |
Completed |
NCT00072150 -
Phase II Trial Of PS-341 (Bortezomib) In Patients With Previously Treated Advanced Urothelial Tract Transitional Cell Carcinoma
|
Phase 2 | |
Completed |
NCT00028756 -
Comparison of Immediate and Delayed Adjuvant Chemotherapy in Treating Patients Who Have Undergone a Radical Cystectomy for Stage III or Stage IV Transitional Cell Carcinoma of the Bladder Urothelium
|
Phase 3 | |
Completed |
NCT02318329 -
Open-Label, Dose-Finding Study Evaluating Safety and PK of FPA144 in Patients With Advanced Solid Tumors
|
Phase 1 | |
Completed |
NCT00407485 -
VEGF Trap in Treating Patients With Recurrent, Locally Advanced, or Metastatic Cancer of the Urothelium
|
Phase 2 | |
Withdrawn |
NCT01639521 -
Gemcitabine Hydrochloride and Cisplatin or High-Dose Methotrexate, Vinblastine, Doxorubicin Hydrochloride, and Cisplatin in Treating Patients With Urothelial Cancer
|
Phase 2 | |
Completed |
NCT00003167 -
Gene Therapy in Treating Patients With Advanced Bladder Cancer
|
Phase 1 | |
Completed |
NCT03081858 -
Proliposomal Intravesical Paclitaxel for Treatment of Low-Grade, Stage Ta, Non Muscle Invasive Bladder Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT02101931 -
A Laser Detection for Bladder Cancer by (Photodynamic) Spectra of Urine
|
Phase 3 | |
Terminated |
NCT00859339 -
Neoadjuvant Cisplatin, Gemcitabine, Sunitinib Malate + Radical Cystectomy for TCC
|
Phase 2 | |
Completed |
NCT00005831 -
Trastuzumab and Combination Chemotherapy in Treating Patients With Locally Recurrent or Metastatic Urinary Tract Cancer
|
Phase 2 | |
Completed |
NCT00706641 -
Neoadjuvant Dasatinib and Radical Cystectomy for Transitional Cell Carcinoma of the Bladder
|
N/A | |
Completed |
NCT01824329 -
Prostate Capsule Sparing Cystectomy and Nerve-sparing Radical Cystoprostatectomy in Men With Bladder Cancer
|
Phase 2 | |
Terminated |
NCT00363883 -
Vorinostat in Treating Patients With Locally Recurrent or Metastatic Cancer of the Urothelium
|
Phase 2 | |
Completed |
NCT00021099 -
Ixabepilone in Treating Patients With Advanced Urinary Tract Cancer
|
Phase 2 | |
Terminated |
NCT01382706 -
Docetaxel and Lapatinib in Metastatic Transitional Cell Carcinoma in Bladder
|
Phase 2 | |
Terminated |
NCT01954173 -
Adjuvant Radiation for High Risk Bladder Cancer
|
N/A | |
Terminated |
NCT00004856 -
Trastuzumab in Treating Patients With Previously Treated, Locally Advanced, or Metastatic Cancer of the Urothelium
|
Phase 2 | |
Terminated |
NCT01282333 -
Veliparib, Cisplatin, and Gemcitabine Hydrochloride in Treating Patients With Advanced Biliary, Pancreatic, Urothelial, or Non-Small Cell Lung Cancer
|
Phase 1 |